Skip to content

AI-Augmented Diagnostic Assessment With ENLIGHT Versus Independent Pathologist Review

AI-Augmented Diagnostic Assessment With ENLIGHT Versus Independent Pathologist Review

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07741058
Acronym
ENLIGHT
Enrollment
25
Registered
2026-08-03
Start date
2026-07-01
Completion date
2026-08-01
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

AI-Augmented Diagnosis, Multimodal AI, Explainable AI, Cancer Diagnosis, Cancer Subtyping, Whole-Slide Imaging

Brief summary

This study will evaluate whether artificial intelligence (AI) can enhance clinicians' accuracy, efficiency, and confidence in distinguishing lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC) and kidney renal papillary cell carcinoma (KIRP) from kidney renal clear cell carcinoma (KIRC) using digitized pathology slides. These subtype classifications are routinely performed by pathologists but can be challenging and time-consuming, particularly in difficult cases. During the study, participating clinicians will review lung and kidney pathology slides under three different conditions: * Unaided Review: Diagnosis without AI assistance. * AI as Double-Check: The clinician first makes an independent diagnosis, after which the AI-generated diagnosis (prediction only or prediction with explanation) is revealed for review. * AI as First-Look: The AI-generated diagnosis (prediction only or prediction with explanation) is presented before the clinician begins the review. Clinicians will be randomly assigned to different review sequences to minimize potential order effects. This study design will enable us to assess the impact of AI assistance on diagnostic accuracy, interpretation time, and clinician confidence.

Detailed description

This study aims to evaluate the effect of artificial intelligence (AI) assistance on clinicians' diagnostic performance in distinguishing lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC) and kidney renal papillary cell carcinoma (KIRP) from kidney renal clear cell carcinoma (KIRC) using digitized hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). ENLIGHT (Explainable Neoplasm Learning In Grounded Histology Terms) will serve as the AI system under evaluation. This is a single-session, within-reader, between-case study in which each reader evaluates distinct sets of cases under all study conditions. The study includes three diagnostic blocks: Block X, in which WSIs are reviewed without AI assistance; Block Y1, in which clinicians make an initial diagnosis before viewing the AI output as a double-check; and Block Y2, in which the AI output is displayed before clinicians begin their review as a first-look aid. Within each AI-assisted block, the prediction-only and prediction-with-explanation sub-blocks are presented in randomized order. Each participating pathologist will review up to 400 de-identified WSIs (up to 200 lung cancer and up to 200 kidney cancer cases). Readers will be randomly assigned to one of four study arms that differ only in the order in which Blocks X, Y1, and Y2 are completed. For each reader, distinct WSIs will be randomly assigned to the diagnostic conditions so that no WSI is reviewed more than once by the same reader. * Arm 1 (X -\> Y1 -\> Y2): Clinicians first complete Block X (Unaided Review), followed by Block Y1 (AI as Double-Check) and then Block Y2 (AI as First-Look). * Arm 2 (X -\> Y2 -\> Y1): Clinicians first complete Block X (Unaided Review), followed by Block Y2 (AI as First-Look) and then Block Y1 (AI as Double-Check). * Arm 3 (Y1 -\> Y2 -\> X): Clinicians first complete Block Y1 (AI as Double-Check), followed by Block Y2 (AI as First-Look), and then Block X (Unaided Review). * Arm 4 (Y2 -\> Y1 -\> X): Clinicians first complete Block Y2 (AI as First-Look), followed by Block Y1 (AI as Double-Check), and then Block X (Unaided Review). For each case, diagnostic accuracy, time to diagnosis, and diagnostic confidence will be recorded. No reader will review the same WSI under more than one condition, thereby eliminating within-reader recall bias. In parallel, the ENLIGHT model will independently generate diagnostic predictions for all WSIs to enable direct benchmarking of AI performance against pathologists and to evaluate the impact of different AI-assisted workflows on diagnostic performance.

Interventions

BEHAVIORALUnaided Review First, Then AI as Double-Check, Then AI as First-Look.

Readers first complete Block X (Unaided) on their assigned subset SX. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.

BEHAVIORALUnaided Review First, Then AI as First-Look, Then AI as Double-Check.

Readers first complete Block X (Unaided) on their assigned subset SX. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.

BEHAVIORALAI as Double-Check First, Then AI as First-Look, Then Unaided Review.

Readers first complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. Then readers complete Block X (Unaided) on their assigned subset SX. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.

BEHAVIORALAI as First-Look First, Then AI as Double-Check, Then Unaided Review.

Readers first complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. Then readers complete Block X (Unaided) on their assigned subset SX. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.

Sponsors

Harvard Medical School (HMS and HSDM)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

for Pathology Slides (i.e., Cases): * Hematoxylin and eosin (H\&E)-stained pathology slides * Final diagnosis confirmed through molecular testing in conjunction with expert pathology evaluation

Exclusion criteria

for Pathology Slides (i.e., Cases): * Poor-quality or unreadable slides * Cases used in AI training Inclusion Criteria for Readers (i.e., Participants): * Board-certified or board-eligible pathologists * Willingness to complete both unaided and AI-assisted review sessions

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performance of cancersPeriprocedural (at the time of slide review)Performance of clinicians (unaided and AI-assisted) for distinguishing LUAD- LUSC and distinguishing KIRP-KIRC, measured in accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and F1.

Secondary

MeasureTime frameDescription
Time to diagnosisPeriprocedural (at the time of slide review)Average time (seconds per case) required to finalize a diagnosis.
Inter-observer variabilityPeriprocedural (at the time of slide review)Agreement among clinicians across conditions, measured using inter-rater reliability metrics (e.g., kappa statistics).
Net benefit after AI exposurePeriprocedural (at the time of slide review)The overall change in diagnostic accuracy attributable to AI assistance.
Clinician confidence levelPeriprocedural (at the time of slide review)Self-reported diagnostic confidence recorded for each case. Scale: 5 - Absolutely Certain; 4 - Mostly Certain; 3 - Unsure; 2 - Very Doubtful; 1 - Random Guess; With 5 being the highest confidence score and 1 being the lowest.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026